SI-BONE, Inc. to Present at 2015 JP Morgan Annual Healthcare Conference

SAN JOSE, Calif., January 6, 2015 -- SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System,® a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that Jeffrey Dunn, President and CEO, will speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 13, 2015 at 11:00 am Pacific Time in Elizabethan D. Mr. Dunn will provide an overview of SI-BONE’s 6 year history including development of the iFuse technology, the burden of SI joint disease, the role of MIS SI joint fusion in the continuum of care of certain SI joint disorders and the growing body of published evidence supporting the clinical and economic benefit of the iFuse Implant System for the treatment of SI joint dysfunction that is a direct result of SI joint disruptions or degenerative sacroiliitis. 

“2015 should be a very exciting and pivotal year for SI-BONE as we anticipate greater adoption and increased payor coverage for our iFuse technology, driven primarily by the new Category I CPT code 27279 that went into effect on January 1st as well as additional peer reviewed publications that will become available within the coming months. I look forward to presenting SI-BONE’s story at this years’ JP Morgan Conference” said Mr. Dunn. 

Clinical publications have identified the SI joint as a pain generator in up to 30% of low back pain patients1,2,3,4 and the prevalence of SI joint pain in post-lumbar fusion, so called “failed back surgery” patients, has been shown to be 43%.5 Of these patients, some may have degenerative sacroiliitis or SIJ disruptions. Initial treatment options for patients with certain SI joint disorders typically involve non-surgical management and, when non-surgical treatment of the SI joint fails, surgical options such as the iFuse procedure may be considered. 

SI-BONE, Inc. received original 510(k) clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010. 

The iFuse Implant System is a minimally invasive surgical option that uses titanium implants coated with a porous, titanium plasma spray (TPS) that acts as an interference surface, designed to help decrease implant motion, provide immediate fixation and allow for biological fixation to support long term fusion. The iFuse System is intended for sacroiliac joint fusion for conditions including SI joint dysfunction that is a direct result of SI joint disruptions and degenerative sacroiliitis. As with all surgical procedures and permanent implants, there are risks and considerations associated with surgery and use of the iFuse Implant. Physicians should refer to the product labeling for a discussion of these risks and patients should talk with their doctors about these risks before deciding if the iFuse Implant is right for them (https://si-bone.com/safetyinfo/) 

  

                                                                           ### 

About SI-BONE, Inc. 
SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to SI joint disorders. The company has developed, and is manufacturing and marketing, less invasive approaches using implants for the treatment of certain SI joint pathology. SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices. SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2014 SI-BONE, Inc. All Rights Reserved.  

1 Bernard TN, Kirkaldy-Willis WH. Recognizing specific characteristics of nonspecific low back pain. Clinical Orthopedics and Related Research. 1987;217:266–80. 
2 Schwarzer AC, Aprill CN, Bogduk N. The Sacroiliac Joint in Chronic Low Back Pain. Spine. 1995;20:31–7. 
3 Maigne JY, Aivaliklis A, Pfefer F. Results of Sacroiliac Joint Double Block and Value of Sacroiliac Pain Provocation Tests in 54 Patients with Low Back Pain. Spine. 1996;21:1889–92. 
4 Sembrano JNa, Polly DW.a How Often is Low Back Pain Not Coming From The Back? Spine. 2009;34:E27–32. 
5 DePalma M, Ketchum JM, Saullo TR. Etiology of Chronic Low Back Pain Patients Having Undergone Lumbar Fusion. Pain Medicine. 2011;12:732-9. 

Disclosures 
a. Investigators in a clinical research study sponsored by SI-BONE, but they have no financial interest in the company.